Communiqués Damora Therapeutics, Inc.

Actions

DMRA

KYG2646Y1044

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 19/08/2026			Varia. 5j.	Varia. 1 janv.
32,44 ^USD	+2,01%		+4,65%	+40,98%

10/08	Damora Therapeutics, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
05/08	Damora Therapeutics lance un essai clinique sur le DMR-001 dans la TE et la myélofibrose	MT

Communiqués

10/08	Damora Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights	AQ
05/08	Damora Therapeutics Initiates Phase 1/1b CLARITY-101 Clinical Trial of DMR-001 in Patients with Mutant Calreticulin-Driven Essential Thrombocythemia and Myelofibrosis	AQ
03/08	Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
17/07	Damora Announces Redomestication from Delaware to Cayman Islands	AQ
01/07	Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
01/06	Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
12/05	Damora Therapeutics : Corporate Presentation	PU
12/05	Damora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights	AQ
04/05	Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	AQ
01/05	Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
23/03	Damora Therapeutics : Appoints Biotechnology Leader Jennifer Jarrett as President and Chief Executive Officer; Adds Two Industry Veterans to Board of Directors	PU
09/03	Galecto Announces Name Change to Damora Therapeutics with Mission to Fundamentally Redefine Care for Patients with Blood Disorders	AQ
05/03	Galecto Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	AQ
04/03	Galecto Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
02/03	Galecto to Participate in Leerink Partners 2026 Global Healthcare Conference	AQ
12/02	Galecto Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $316.3 Million	AQ
11/02	Galecto Announces Pricing of $275 Million Underwritten Public Offering	AQ
10/02	Galecto Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock	AQ
12/01	Galecto : Corporate Presentation	PU
12/01	Galecto Highlights Key Strategic Priorities and Anticipated 2026 Milestones	AQ
06/01	Galecto Announces Key Additions to Leadership Team	AQ
16/12	Galecto, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	AQ
10/11	Galecto : Damora Therapeutics Corporate Overview	PU
10/11	Galecto Announces Acquisition of Damora Therapeutics	AQ
06/11	Galecto Reports Third Quarter 2025 Operating and Financial Results	AQ